Anna S. Lok

69.8k total citations · 17 hit papers
557 papers, 48.3k citations indexed

About

Anna S. Lok is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Anna S. Lok has authored 557 papers receiving a total of 48.3k indexed citations (citations by other indexed papers that have themselves been cited), including 468 papers in Epidemiology, 464 papers in Hepatology and 57 papers in Surgery. Recurrent topics in Anna S. Lok's work include Hepatitis C virus research (365 papers), Liver Disease Diagnosis and Treatment (354 papers) and Hepatitis B Virus Studies (329 papers). Anna S. Lok is often cited by papers focused on Hepatitis C virus research (365 papers), Liver Disease Diagnosis and Treatment (354 papers) and Hepatitis B Virus Studies (329 papers). Anna S. Lok collaborates with scholars based in United States, China and Hong Kong. Anna S. Lok's co-authors include Brian J. McMahon, Jorge A. Marrero, Robert J. Fontana, Hari S. Conjeevaram, Ching‐Lung Lai, Joel K. Greenson, Henry Lik‐Yuen Chan, Chun‐Tao Wai, Marc G. Ghany and Munira Hussain and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Anna S. Lok

550 papers receiving 47.0k citations

Hit Papers

A Simple Noninvasive Index Can Predict Both Significant F... 1991 2026 2002 2014 2003 2018 2009 2007 2014 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
    2003 3.4k citations Robert J. Fontana, Jorge A. Marrero et al. Hepatology profile →
  2. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
    2018 2.6k citations Norah A. Terrault, Anna S. Lok et al. Hepatology profile →
  3. Chronic hepatitis B: Update 2009 #
    2009 2.2k citations Anna S. Lok et al. Hepatology profile →
  4. Chronic hepatitis B
    2007 2.1k citations Anna S. Lok et al. Hepatology profile →
  5. Hepatitis B virus infection
    2014 1.2k citations Anna S. Lok et al. profile →
  6. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
    2006 1.1k citations Anna S. Lok et al. profile →
  7. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
    2006 900 citations Ching‐Lung Lai, Anna S. Lok et al. profile →
  8. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
    1991 649 citations Anna S. Lok, Raymond Liang et al. Gastroenterology profile →
  9. Management of hepatitis B: 2000—Summary of a workshop
    2001 610 citations Anna S. Lok et al. Gastroenterology profile →
  10. Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    2003 596 citations Anna S. Lok, Ching‐Lung Lai et al. Gastroenterology profile →
  11. α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma
    2009 557 citations Jorge A. Marrero, K. Rajender Reddy et al. Gastroenterology profile →
  12. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
    2012 454 citations Anna S. Lok et al. profile →
  13. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
    2015 391 citations Anna S. Lok et al. Hepatology profile →
  14. Use of Liver Imaging and Biopsy in Clinical Practice
    2017 291 citations Anna S. Lok et al. profile →
  15. Hepatitis B
    2023 264 citations Anna S. Lok et al. profile →
  16. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    2022 140 citations Anna S. Lok et al. profile →
  17. The scientific basis of combination therapy for chronic hepatitis B functional cure
    2023 88 citations Anna S. Lok, Norah A. Terrault et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna S. Lok United States 105 40.9k 39.5k 3.9k 3.7k 2.7k 557 48.3k
Stefan Zeuzem Germany 101 32.8k 0.8× 34.2k 0.9× 4.1k 1.1× 5.0k 1.3× 5.3k 1.9× 1.0k 47.0k
K. Rajender Reddy United States 88 24.9k 0.6× 28.3k 0.7× 5.3k 1.4× 3.9k 1.0× 2.4k 0.9× 586 37.2k
Zachary Goodman United States 88 33.3k 0.8× 31.0k 0.8× 4.5k 1.1× 3.4k 0.9× 3.0k 1.1× 299 42.1k
Adrian M. Di Bisceglie United States 89 24.4k 0.6× 24.7k 0.6× 2.5k 0.6× 2.2k 0.6× 4.0k 1.5× 385 34.5k
Ding‐Shinn Chen Taiwan 95 29.0k 0.7× 27.7k 0.7× 2.5k 0.6× 3.2k 0.9× 5.2k 1.9× 772 38.7k
Ching‐Lung Lai Hong Kong 95 28.0k 0.7× 27.6k 0.7× 3.8k 1.0× 4.3k 1.1× 2.5k 0.9× 598 36.2k
Jay H. Hoofnagle United States 109 30.6k 0.7× 30.1k 0.8× 4.2k 1.1× 3.8k 1.0× 3.3k 1.2× 393 43.8k
Thierry Poynard France 93 36.1k 0.9× 33.9k 0.9× 4.3k 1.1× 2.8k 0.8× 2.0k 0.7× 427 43.7k
Thomas Berg Germany 73 20.4k 0.5× 20.3k 0.5× 1.9k 0.5× 3.2k 0.9× 2.1k 0.8× 726 28.1k
Henry Lik‐Yuen Chan Hong Kong 90 20.9k 0.5× 16.2k 0.4× 2.9k 0.8× 2.0k 0.5× 3.4k 1.2× 440 28.2k

Countries citing papers authored by Anna S. Lok

Since Specialization
Citations

This map shows the geographic impact of Anna S. Lok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna S. Lok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna S. Lok more than expected).

Fields of papers citing papers by Anna S. Lok

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna S. Lok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna S. Lok. The network helps show where Anna S. Lok may publish in the future.

Co-authorship network of co-authors of Anna S. Lok

This figure shows the co-authorship network connecting the top 25 collaborators of Anna S. Lok. A scholar is included among the top collaborators of Anna S. Lok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna S. Lok. Anna S. Lok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huth, Karoline, et al.. (2024). Exploring the mechanisms underlying increased risk of depressive disorder in ethnic minority populations in Europe: A causal loop diagram. Social Science & Medicine. 351. 116977–116977. 1 indexed citations
2.
Singal, Amit G., Neehar D. Parikh, Kirti Shetty, et al.. (2024). Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study. The American Journal of Gastroenterology. 119(11). 2251–2258. 3 indexed citations
3.
Feld, Jordan J., Abdus S. Wahed, Michael Fried, et al.. (2023). Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial. The American Journal of Gastroenterology. 118(7). 1226–1236. 13 indexed citations
4.
Gairing, Simon Johannes, Lisa Zarantonello, Stefania Gioia, et al.. (2023). Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival. Journal of Internal Medicine. 295(3). 331–345. 13 indexed citations
5.
Lok, Anna S., et al.. (2022). Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort. Digestive Diseases and Sciences. 67(11). 5300–5308. 9 indexed citations
6.
Feld, Jordan J., Wendy C. King, Marc G. Ghany, et al.. (2022). Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology. 21(6). 1503–1512.e4. 3 indexed citations
7.
Harding‐Theobald, Emily, Jeremy Louissaint, Bharat Maraj, et al.. (2021). Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics. 54(7). 890–901. 95 indexed citations
8.
Torres, Harrys A., Anna S. Lok, María E. Suarez‐Almazor, et al.. (2020). Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Supportive Care in Cancer. 29(1). 97–105. 1 indexed citations
9.
Lok, Anna S., Mark Sulkowski, Jens Kort, et al.. (2019). Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 157(6). 1506–1517.e1. 34 indexed citations
10.
Waarde, Jeroen A. van, et al.. (2019). [Electroconvulsion therapy for persistent depression in the Netherlands; very low application rate].. PubMed. 61(1). 16–21. 5 indexed citations
11.
12.
Kanwal, Fasiha, Anna S. Lok, & Hashem B. El‐Serag. (2013). CDC and USPSTF 2012 Recommendations for Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages. Gastroenterology. 144(3). 478–481. 5 indexed citations
13.
Rakoski, Mina O., Ryan J. McCammon, John D. Piette, et al.. (2011). Burden of Cirrhosis on Older Americans and Their Families. Hepatology. 55(1). 184–191. 135 indexed citations
14.
Shetty, Kirti, et al.. (2008). Prevalence and Significance of Occult Hepatitis B in a Liver Transplant Population With Chronic Hepatitis C. Liver Transplantation. 14(4). 534–540. 48 indexed citations
15.
Fung, Scott & Anna S. Lok. (2005). Update on viral hepatitis in 2004. Current Opinion in Internal Medicine. 4(4). 359–366. 16 indexed citations
16.
Fontana, Robert J., et al.. (2002). Results of a Prospective, Randomized, Controlled Trial. Journal of Clinical Gastroenterology. 34(2). 177–182. 14 indexed citations
17.
Lau, Kui Kai, Anna S. Lok, Raymond Liang, et al.. (1997). Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology. 25(6). 1497–1501. 147 indexed citations
18.
Karayiannis, Peter, David M. Novick, Anna S. Lok, et al.. (1985). Hepatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen.. BMJ. 290(6485). 1853–1855. 58 indexed citations
19.
Karayiannis, Peter, et al.. (1985). Hepatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen. BMJ. 291(6493). 482.2–482. 3 indexed citations
20.
Lok, Anna S., Iain Lindsay, Peter J. Scheuer, & Howard C. Thomas. (1985). Clinical and histological features of delta infection in chronic hepatitis B virus carriers.. Journal of Clinical Pathology. 38(5). 530–533. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Zeuzem Breakdown of academic impact, for papers by K. Rajender Reddy Breakdown of academic impact, for papers by Zachary Goodman Breakdown of academic impact, for papers by Adrian M. Di Bisceglie Breakdown of academic impact, for papers by Ding‐Shinn Chen Breakdown of academic impact, for papers by Ching‐Lung Lai Breakdown of academic impact, for papers by Jay H. Hoofnagle Breakdown of academic impact, for papers by Thierry Poynard Breakdown of academic impact, for papers by Thomas Berg Breakdown of academic impact, for papers by Henry Lik‐Yuen Chan
Rankless by CCL
2026